Document resource
Migraine is a highly prevalent disabling disorder affecting approximately 1 billion people worldwide.1 Its pathophysiology involves activation and sensitisation of the trigeminovascular system, resulting in the release of neuropeptides, such as pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) and calcitonin gene-related peptide (CGRP).2